logo

CRBU

Caribou Biosciences·NASDAQ
--
--(--)
--
--(--)
6.55 / 10
Outperform

CRBU's fundamental score of 6.5/10 indicates good quality, driven by favorable PB-ROE, Asset-MV, Revenue-MV, Profit-MV, Cash-MV, and Gross profit margin factors. However, Current and Fixed assets turnover ratios are suboptimal. Overall, the balance sheet and profitability remain strong, supporting an Outperform stance despite minor efficiency concerns.

Fundamental(6.55)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-2.85
Score2/3
Weight16.98%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight6.54%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight14.95%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight11.14%
1M Return7.79%
PB-ROE
Value0.06
Score3/3
Weight17.50%
1M Return11.47%
Current assets turnover ratio
Value0.04
Score0/3
Weight-2.04%
1M Return-1.88%
Fixed assets turnover ratio
Value0.54
Score1/3
Weight-1.77%
1M Return-1.64%
Asset-MV
Value-0.50
Score3/3
Weight25.86%
1M Return14.99%
Cash-MV
Value-0.07
Score2/3
Weight11.16%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.33%
1M Return-0.30%
Is CRBU fundamentally strong?
  • CRBU scores 6.55/10 on fundamentals and holds a Discounted valuation at present. Backed by its -61.62% ROE, -1690.45% net margin, -0.93 P/E ratio, 1.03 P/B ratio, and -2.41% earnings growth, these metrics solidify its Outperform investment rating.